According to latest report, the global antidiabetics market size was USD 82.85 billion in 2023, calculated at USD 93.00 billion in 2024, and is expected to reach around USD 263.12 billion by 2033, expanding at a CAGR of 12.25% from 2024 to 2033. The North America market accounted for the largest share of 42.11% in 2023.
Get Sample Copy of Report@ https://www.novaoneadvisor.com/report/sample/8566
The global antidiabetics market has witnessed substantial growth in recent years, driven by the rising prevalence of diabetes, increasing awareness about diabetes management, advancements in pharmaceutical technology, and a growing elderly population. This market encompasses various products used to manage diabetes, including insulin, oral hypoglycaemic agents, and non-insulin injectable drugs.
The incidence of diabetes is on the rise globally, with significant increases in both Type 1 and Type 2 diabetes cases. Factors contributing to this trend include unhealthy lifestyles, obesity, genetic predisposition, and aging populations. Increased awareness about diabetes and its complications has led to earlier diagnosis and treatment. Governments, healthcare organizations, and pharmaceutical companies are actively involved in educational campaigns and screening programs, further driving market growth.
Antidiabetics Market Key Takeaways
- The North America region has accounted highest market share of around 42.11% in 2023.
- Asia Pacific market is estimated to grow at the fastest rate during the forecast period.
- GLP-1 receptor agonists segment dominated the market in 2023 with a share of 35.96% and is expected to grow at the fastest CAGR by 2033.
- Diabetes type 2 segment dominated the market in 2023 with a market share of 79.91% and is expected to grow at the fastest CAGR from 2024 to 2033.
- Intravenous segment dominated the market in 2023 with a share of 42.81%.
- Subcutaneous segment is estimated to grow at the fastest rate during the forecast period.
- Hospital pharmacies segment held the largest market share of 50.11% in 2023.
- Online pharmacies segment is estimated to grow at the fastest CAGR from 2024 to 2033.
Growth Factors
- The rising geriatric population and the growing prevalence of unhealthy lifestyles are driving the growth of the market.
- The antidiabetics market is observed to be driven with the rising investments in research and development activities.
- The rising glucose intolerance in the population and the growing prevalence of type 2 diabetes in the younger population also enhance the growth of the market.
- The rising government initiatives for controlling the growing number of diabetes patients with the awareness campaign by the various regional governments is driving the growth of the antidiabetics market.
U.S. Antidiabetics Market Size and Companies
The U.S. antidiabetics market size was estimated at USD 34.71 billion in 2024 and is projected to hit around USD 98.37 billion by 2033, growing at a CAGR of 12.27% during the forecast period from 2024 to 2033.
North America market accounted for the largest share of 42.11% in 2023. The region has a notably high prevalence of diabetes, primarily type 2 diabetes, which has increased due to lifestyle changes and an aging population. Additionally, the region’s well-developed healthcare infrastructure and high healthcare expenditure allow for extensive diabetes management and treatment options, contributing to the market's dominance. North America is home to several prominent pharmaceutical companies and research institutions specializing in diabetic care and innovation. These organizations continuously develop and introduce new antidiabetic drugs and technologies, fostering growth in the market.
U.S. Antidiabetics Market Trends
The market in the U.S. is expected to grow over the forecast period due to several factors, including advancements in clinical research, increasing number of FDA-approved drugs, and a strong R&D pipeline. According to an article published by the Frontiers in June 2022, nearly 100 . antihyperglycemic agents are currently being evaluated for type 2 diabetes and 60 drugs have been approved.
Europe Antidiabetics Market Trends
Europe market is experiencing significant growth majorly due to high prevalence and the increasing financial burden of diabetes. It is one of the leading cause of death in the region, however, the prevalence & mortality rate vary significantly between European countries.
UK antidiabetics market is driven by increasing prescription rate as compared to the historic years and rising demand for innovative antidiabetics as the government focuses on improving public health.
The antidiabetics market in France is expected to grow over the forecast period due to rising awareness about the management of the disease. DPP-4 inhibitors and GLP-1 receptor agonists were the most prescribed drug class in 2021.
Germany antidiabetics market is expected to grow at a lucrative rate over the forecast period. This can be attributed to the ongoing advancements by public and private organizations, rising geriatric population, and focus on R&D by various companies headquartered in Germany
Asia Pacific Antidiabetics Market Trends
Asia Pacific market is estimated to grow at the fastest rate during the forecast period. Asia Pacific has witnessed a significant surge in diabetic cases, particularly type 2 diabetes, due to changing lifestyles, urbanization, and dietary habits. The region is home to a large and growing population, making it a substantial market for diabetes management and treatment. Moreover, the trend is the expansion of telemedicine and digital health solutions in the region. COVID-19 accelerated the adoption of remote healthcare services, including teleconsultations and digital platforms for diabetes management. The adoption of digital health solutions, positioning it as a key growth area for diabetes’s related products and services in the coming years.
The antidiabetics market in China is expected to grow over the forecast period owing to the high prevalence of the condition. According to a leading endocrinologist in China, nearly 114 million people are living with diabetes in China which is 40%-60% of the total population of diabetes globally.
Japan antidiabetics market is expected to grow over the forecast period due to the presence of well-established healthcare system. According to the IDF, over 7.4 million Japanese individuals were living with diabetes in 2020. Westernized lifestyle, unhealthy diet, lack of exercise, and aging population are major risk factors boosting the prevalence of diabetes in the country.
Latin America Antidiabetics Market Trends
Latin America market was identified as a lucrative region in this industry. A large section of society in South America is aging rapidly, which has led to an increase in healthcare expenditure and is driving market growth in the region.
The antidiabetics market in Brazil is expected to grow over the forecast period. Over the years, Brazil has enacted several changes to introduce new financing methods, establish new service organization types, enhance the distribution of doctors, and execute a range of quality improvement programs and policy frameworks. This also demonstrates potential areas for further and ongoing advancements in diabetes therapy.
MEA Antidiabetics Market Trends
MEA market is primarily driven by increasing focus of government to curb the alarming prevalence of diabetes in MEA countries and shift in dietary and lifestyle patterns leading to obesity and other metabolic disorders.
The antidiabetics market in Saudi Arabia is experiencing significant growth, driven by substantial government investment in pharmaceuticals. Organizations such as the Saudi Diabetes & Endocrine Association (SDEA) are creating general awareness among the population. Additionally, growing technological advancements in R&D of drug delivery is expected to increase the prescription rate for a product, driving the market.
Antidiabetics Market Dynamics
Driver:
Technological advancements
Integration of digital health technologies, including mobile apps, wearable devices, and telemedicine, to monitor and manage diabetes in real-time. Utilizing AI and big data analytics to predict diabetes trends, personalize treatments, and improve patient adherence to medication. Expansion of CGM systems providing accurate, real-time glucose readings and better glycaemic control.
Restraint:
Risk of adverse effects and regulatory hurdles
Some antidiabetic drugs are associated with adverse side effects, such as gastrointestinal issues, weight gain, and cardiovascular risks. These side effects can deter patient adherence to prescribed treatments and affect market acceptance. The stringent regulatory requirements for the approval of new antidiabetic drugs can delay market entry. The rigorous clinical trial processes and the need for extensive safety and efficacy data can be time-consuming and costly for pharmaceutical companies.
Opportunity:
Personalized medicine
Development of personalized antidiabetic medications based on genetic and phenotypic profiles to improve efficacy and reduce side effects. Growth in biologic drugs and biosimilars offering new treatment options with potentially lower costs and improved patient outcomes. Research and development of combination therapies that target multiple pathways involved in diabetes to enhance treatment outcomes.
Appropriate antibiotic use
What is unnecessary antibiotic use?
Unnecessary antibiotic use happens when a person takes antibiotics they don't need, like for colds and flu. Unnecessary use also happens when a person takes antibiotics for infections that are sometimes caused by bacteria that do not always need antibiotics, like many sinus infections and some ear infections.
What is misuse of antibiotics?
Misuse of antibiotics happens when a person takes the wrong antibiotic, the wrong dose of an antibiotic or an antibiotic for the wrong length of time. Talk to your doctor about the best treatment for your illness and steps you can take to feel better when you don't need an antibiotic. Never pressure your doctor to prescribe an antibiotic. Do not save antibiotics for later.
Immediate Delivery Available, Get Full Access@ https://www.novaoneadvisor.com/report/checkout/8566
Antidiabetics Market Segments Insights
By Drug Class Insights
GLP-1 receptor agonists segment dominated the market in 2023 with a share of 35.96% and is expected to grow at the fastest CAGR by 2033. This growth can be attributed to its high efficacy for managing type 2 diabetes and its potential advantages to patients, such as being effective in regulating blood sugar levels and promoting insulin production, making them a preferred therapeutic choice for diabetes management. The high growth rate of this segment is underpinned by its ability to address critical medical needs and deliver tangible benefits to patients.
The advancements in treatment modalities, increasing awareness about diabetes management, and the introduction of patient-friendly options like oral GLP-1 receptor agonists have all contributed to the growing dominance of the segment. The introduction of innovative treatment options, the ongoing efforts to enhance patient experiences, and the continuous exploration of GLP-1 receptor agonists' potential in diabetes management contribute to the anticipated robust growth. For instance, in June 2023, Pfizer announced that it is actively progressing its clinical development program for GLP-1 receptor agonists (GLP-1-RAs), focusing on danuglipron, the first full agonist oral candidate. This effort is aimed at addressing obesity and type 2 diabetes mellitus. Pfizer's commitment to advancing danuglipron towards late-stage development demonstrates its dedication to providing innovative solutions for managing these health challenges.
By Diabetes Type Insights
Diabetes type 2 segment dominated the market in 2023 with a market share of 79.91% and is expected to grow at the fastest CAGR from 2024 to 2033. This growth be attributed to the increasing prevalence of this chronic condition globally. According to the IMHE report June 2023, the global diabetes cases to soar from 529 million to 1.3 billion by 2050 As more individuals are diagnosed with type 2 diabetes, the demand for effective management and treatment options grows, leading to the segment's substantial market share. The increasing awareness about diabetes prevention, management, and the development of innovative therapies and technologies are projected to drive this growth.
The rising need to address the healthcare burden posed by type 2 diabetics and its associated complications is motivating both research and industry to invest in solutions that offer better patient outcomes and contribute to this market segment's ongoing dominance. For instance, in July 2023, Dexcom, a prominent global leader in real-time continuous glucose monitoring (rtCGM) solutions for individuals with diabetes, received Health Canada's approval for its advanced Dexcom G7 Continuous Glucose Monitoring System. This innovative system is now authorized for use by individuals of all diabetic types aged two years and older, offering enhanced diabetic management capabilities. These advancements support easy monitoring and treatment of the condition, thereby boosting the demand for treatments.
By Route of Administration Insights
Intravenous segment dominated the market in 2023 with a share of 42.81%. The intravenous administration of antidiabetic medications offers immediate and precise control over blood glucose levels, proving particularly invaluable during critical scenarios like diabetic ketoacidosis or hyperglycemic emergencies. This immediate impact on glucose regulation positions intravenous treatments as pivotal for addressing acute diabetic complications. Moreover, advancements and drug approvals in intravenous drug formulations and delivery technologies have improved the efficacy and safety of this approach, sustaining its market dominance. For instance, in May 2022, Mounjaro (tirzepatide) injection received approval by the U.S. Food and Drug Administration. The injection is an advanced treatment enhancing blood sugar management for adults with type 2 diabetes. Mounjaro demonstrated remarkable efficacy, outperforming other diabetes treatments in clinical trials.
Subcutaneous segment is estimated to grow at the fastest rate during the forecast period. The subcutaneous method of giving diabetes medication is easier for patients. They can give themselves shots or use less invasive devices, so they don't have to see the doctor or stay in the hospital as often. Subcutaneous diabetic drugs also work quickly, helping control blood sugar better, which is really important for people with diabetes. Some prominent players are working with tech giants to make smart insulin pens that connect to phone apps. This makes it easier to track blood sugar and get advice on how much insulin to use. This shows how diabetes care is changing and getting better for patients. For instance, in August 2023, Insulet released the Omnipod 5 Automated Insulin Delivery System in Germany, which is a big step forward in how to treat diabetes. The increasing adoption of these novel delivery segments is projected to drive the segment growth.
By Distribution Channel Insights
Hospital pharmacies segment held the largest market share of 50.11% in 2023. Hospitals are often the primary care providers for patients with diabetes, especially those with severe or complicated cases. This central role allows hospital pharmacies to have a strong influence in shaping treatment protocols and prescribing decisions. Moreover, they have access to a wide range of antidiabetic medications and resources, ensuring that patients receive the most suitable and effective treatments this comprehensive approach fosters patient trust and loyalty, further solidifying the hospital pharmacies' dominant position in the market.
In a major development, a major pharmaceutical company has entered into a strategic partnership with a prominent hospital network. As part of this collaboration, the pharmaceutical company has exclusively provided its latest antidiabetic medication to the hospital network, reinforcing the hospitals' role in prescribing and administering the drug. For example, in August 2023, Shields Health Solutions, a leading specialty pharmacy accelerator, joined forces with Erlanger, a respected multi-hospital health system based in Tennessee. Together, they launched an innovative specialty pharmacy program within the hospital pharmacy. This initiative aims to enhance access to specialized pharmacy services for patients dealing with complex, chronic conditions, focusing on cost reduction, treatment expansion, improved medication management, and overall health enhancement.
Online pharmacies segment is estimated to grow at the fastest CAGR from 2024 to 2033. The growth of the segment is due to the ease of ordering medications from the comfort of their homes and having them delivered to their doorstep, diabetic individuals no longer face the hassle of visiting physical pharmacies or waiting in queues. For instance, in November 2020, Amazon.com, Inc. introduced two pharmacy services for prescription medications. Amazon Pharmacy enables customers to complete pharmacy transactions seamlessly on their desktop or mobile devices via the Amazon App. This accessibility significantly enhances medication adherence, a critical factor in disease management. Moreover, the vast availability of antidiabetic drugs from different brands and generic alternatives online empowers patients with choices, fostering competition and potentially lowering overall treatment costs.
Immediate Delivery Available, Get Full Access@ https://www.novaoneadvisor.com/report/checkout/8566
Antidiabetics Market Recent Developments
- In May 2024, Sanofi Limited launched Soliqua, an antidiabetic drug, in India. Soliqua is used to treat type 2 diabetes & obesity and is a daily once injectable.
- In January 2024, Glenmark launched the first biosimilar of Liraglutide in India. Liraglutide is a popular drug used to treat type 2 diabetes mellitus in adults. The drug was planned to be marketed under the brand name Lirafit for USD 1.20 and will be available only under prescription. The biosimilar launch will make the drug more accessible to patients in India as the cost will lower up to 70%.
- In June 2023, the FDA approved two drugs, Synjardy and Jardiance, new class of medications for pediatric type 2 diabetes. These drugs can be administered in children aged 10 and above.
Related Report
Cancer Immunotherapy Market : The global cancer immunotherapy market size was valued at USD 126.19 billion in 2023 and is projected to surpass around USD 296.01 billion by 2033, registering a CAGR of 8.9% over the forecast period of 2024 to 2033.
Antibiotics Market : The global antibiotics market size was valued at USD 51.19 billion in 2023 and is projected to surpass around USD 85.80 billion by 2033, registering a CAGR of 5.3% over the forecast period of 2024 to 2033.
Biotechnology Market : The global biotechnology market size was estimated at USD 1.54 Trillion in 2023 and is projected to hit around USD 5.68 Trillion by 2033, growing at a CAGR of 13.95% during the forecast period from 2024 to 2033.
Clinical Trials Market : The global clinical trials market size was estimated at USD 81.90 billion in 2023 and is projected to hit around USD 153.59 billion by 2033, growing at a CAGR of 6.49% during the forecast period from 2024 to 2033.
Biomarkers Market: The global Biomarkers market size was estimated at USD 81.19 billion in 2023 and is projected to hit around USD 284.76 billion by 2033, growing at a CAGR of 13.37% during the forecast period from 2024 to 2033.
Immunotherapy Drugs Market : The global immunotherapy drugs market size was valued at USD 240.19 billion in 2023 and is projected to surpass around USD 1,300.38 billion by 2033, registering a CAGR of 18.4% over the forecast period of 2024 to 2033.
Antidiabetics Market Top Key Companies:
The following are the leading companies in the antidiabetics market. These companies collectively hold the largest market share and dictate industry trends.
- AstraZeneca plc
- Bayer AG
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Boehringer Ingelheim
- Bristol-Myers Squibb Company
- Pfizer, Inc.
- Johnson & Johnson Services Inc.
- Merck & Co. Inc
- Novartis AG
Antidiabetics Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Antidiabetics market.
By Drug Class
- Insulin
- Insulin By Type
- Long-acting insulin
- Premix insulin
- Fast-acting insulin
- Human insulin
- Insulin By Type
- GLP-1 Receptor Agonists
- DPP- 4 Inhibitors
- SGLT2 Inhibitors
- Others
By Diabetes Type
- Type 1
- Type 2
By Route of administration
- Oral
- Subcutaneous
- Intravenous
By Distribution Channel
- Online pharmacies
- Hospital Pharmacies
- Retail pharmacies
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa (MEA)
Immediate Delivery Available | Buy This Premium Research
https://www.novaoneadvisor.com/report/checkout/8566
Frequently Asked Questions
- What geographic regions does your market research cover for the Antidiabetics market?
- We have a global reach, with expertise spanning across continents, including North America, Europe, Asia-Pacific, Latin America, and the Middle East. We leverage a combination of primary and secondary research methodologies to offer country-level analysis.
- How does your firm conduct cross-sectional analysis for the Antidiabetics market?
- We conduct cross-sectional analysis by examining data from different individuals at a single point in time to identify patterns and trends across diverse segments of the market.
- Can your firm customize market research solutions to meet specific client needs?
- Our experienced team works closely with clients to gain a thorough understanding of their business goals and target markets. We have the expertise and flexibility to develop bespoke research solutions.
- Do you offer ongoing support or consultation to clients after the completion of a market research project?
- Our team of experienced analysts is available to address any questions, concerns and needs that may arise following the delivery of the report.
- Can your market research firm help with competitor analysis for Antidiabetics market?
- Through a combination of quantitative and qualitative research methodologies, we meticulously assess the strengths, weaknesses, strategies, and market positioning of your competitors.
Procure Complete Report (220+ Pages PDF with Insights, Charts, Tables, and Figures) @ https://www.novaoneadvisor.com/report/checkout/8566
Call: USA: +1 650 460 3308 | IND: +91 87933 22019 |Europe: +44 2080772818
Email: sales@novaoneadvisor.com
